No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease

被引:15
|
作者
Schernthaner, GH
Plank, C
Minar, E
Bieglmayer, C
Koppensteiner, R
Schernthaner, G
机构
[1] Med Univ Vienna, Dept Internal Med 2, Div Angiol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Radiol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Med & Chem Lab Diagnost, A-1090 Vienna, Austria
[4] Rudolfstiftung Hosp, Dept Internal Med 1, Vienna, Austria
关键词
folic acid; haemostasis; homocysteine; inflammation; peripheral arterial occlusive disease;
D O I
10.1111/j.1365-2362.2006.01639.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Although peripheral arterial occlusive disease (PAOD) is significantly associated with elevated homocysteine levels, the clinical relevance of hyperhomocysteinaemia for the prevention and progression of PAOD is still unknown. Materials and methods A total of 65 patients suffering from symptomatic PAOD with elevated homocysteine levels were randomized onto placebo or B-vitamins (50 mg thiaminhydrochlorid, 50 mg pyridoxine, and 0.05 mg cyanocobalamin), plus 5 mg folic acid daily for 6 weeks. Serum levels of folic acid, vitamin B12, creatinine, ultra-sensitive C-reactive protein (usCRP), interleukin (IL)-6, IL-8, IL-18, monocyte-chemo-attractant-protein-1 (MCP-1) and plasma levels of homocysteine, tissue factor (TF) and tissue factor pathway inhibitor (TFPI) were determined on the 1st day and 42nd day. Primary outcome was reduction of homocysteine, secondary outcomes were reduction of usCRP, IL-6, IL-8, Il-18, MCP-1, TF and TFPI. Results The mean reduction of homocysteine concentration was 33% (95%CI 33.36-55.76, or 18.9 +/- 5.4 mu mol L-1-12.6 +/- 2.8 mu mol L-1, P = 0) in the B-vitamin group compared with 1% in the placebo group. Folic acid (P = 0) and vitamin B12 (P = 0) increased significantly in the verum group, but both remained unchanged in the control group. No treatment effect of lowering of homocysteine on any markers of haemostasis (TF, TFPI) or inflammation (usCRP, IL-6, IL-8, IL-18 and MCP-1) was observed. Conclusion Although homocysteine is associated with vascular disease risk in the general population and in particular with PAOD, marked lowering of homocysteine concentrations by folic acid and B-vitamin supplementation does not influence inflammatory responses involving usCRP, IL-6, IL-8, IL-18 and MCP-1, nor tissue factor. These results provide evidence against a major effect of hyperhomocysteinaemia on vascular chronic inflammation or coagulation in patients with symptomatic peripheral arterial occlusive disease.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [1] Difference in the homocysteine-lowering effect of folic acid in haemodialysis patients with and without occlusive vascular disease
    Descombes, E
    Boulat, O
    Bersier, LF
    Fellay, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (03) : 585 - 589
  • [2] Homocysteine-lowering therapy in renal disease
    Austen, SK
    Coombes, JS
    Fassett, RG
    CLINICAL NEPHROLOGY, 2003, 60 (06) : 375 - 385
  • [3] Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials
    Clarke, Robert
    Halsey, Jim
    Bennett, Derrick
    Lewington, Sarah
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (01) : 83 - 91
  • [4] Role of lipid lowering therapy in patients with peripheral arterial occlusive disease
    Wittlinger, T
    Kröger, K
    HERZ, 2004, 29 (01) : 12 - 16
  • [5] Effect of homocysteine-lowering therapy on vascular endothelial function and exercise performance in coronary patients with hyperhomocysteinaemia
    Dinckal, MH
    Aksoy, N
    Aksoy, M
    Davutoglu, V
    Soydinc, S
    Kirilmaz, A
    Dinckal, N
    Akdemir, Y
    ACTA CARDIOLOGICA, 2003, 58 (05) : 389 - 396
  • [6] The effect of homocysteine-lowering therapy on vascular endothelial function and exercise performance in coronary patients with hyperhomocysteinaemia
    Akdemir, I
    Aksoy, M
    Aksoy, N
    Gursurer, M
    Davutoglu, V
    Emre, A
    Ersek, B
    Oc, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 129 - 129
  • [7] Homocysteine-lowering or antioxidant therapy for bone loss in Parkinson's disease
    Chung, S. J.
    Lee, S. H.
    Kim, M. J.
    Kim, B. -J.
    Kim, S. R.
    Chun, S.
    Ryu, J. S.
    Kim, G. S.
    Lee, M. C.
    Koh, J. -M.
    MOVEMENT DISORDERS, 2010, 25 (07) : S293 - S293
  • [8] Homocysteine-Lowering Therapy or Antioxidant Therapy for Bone Loss in Parkinson's Disease
    Lee, Seung Hun
    Kim, Mi Jung
    Kim, Beom-Jun
    Kim, Sung Reul
    Chun, Sail
    Ryu, Jin Sook
    Kim, Ghi Su
    Lee, Myoung Chong
    Koh, Jung-Min
    Chung, Sun Ju
    MOVEMENT DISORDERS, 2010, 25 (03) : 332 - 340
  • [9] Homocysteine-lowering interventions in chronic kidney disease
    Badri, Shirinsadat
    Vahdat, Sahar
    Seirafian, Shiva
    Pourfarzam, Morteza
    Gholipur-Shahraki, Tahereh
    Ataei, Sara
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2021, 10 (03) : 114 - 124
  • [10] Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients
    Mashavi, M.
    Hanah, R.
    Boaz, M.
    Gavish, D.
    Matas, Z.
    Fux, A.
    Shargorodsky, M.
    ATHEROSCLEROSIS, 2008, 199 (02) : 362 - 367